Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurogene (NGNE) Common Equity: 2018-2025

Historic Common Equity for Neurogene (NGNE) over the last 6 years, with Sep 2025 value amounting to $265.5 million.

  • Neurogene's Common Equity rose 93.24% to $265.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $265.5 million, marking a year-over-year increase of 93.24%. This contributed to the annual value of $310.4 million for FY2024, which is 66.85% up from last year.
  • Per Neurogene's latest filing, its Common Equity stood at $265.5 million for Q3 2025, which was down 2.82% from $273.3 million recorded in Q2 2025.
  • Neurogene's 5-year Common Equity high stood at $310.4 million for Q4 2024, and its period low was $75.2 million during Q3 2023.
  • Its 3-year average for Common Equity is $184.2 million, with a median of $170.8 million in 2024.
  • Data for Neurogene's Common Equity shows a peak YoY surged of 109.91% (in 2024) over the last 5 years.
  • Quarterly analysis of 3 years shows Neurogene's Common Equity stood at $186.0 million in 2023, then surged by 66.85% to $310.4 million in 2024, then surged by 93.24% to $265.5 million in 2025.
  • Its Common Equity stands at $265.5 million for Q3 2025, versus $273.3 million for Q2 2025 and $291.8 million for Q1 2025.